Clinical pharmacology and therapeutics, 46(3), 359-366 (1989-09-01)
Little is known regarding the biotransformation of drugs in Down's syndrome. In particular, there are no published studies that examine metabolic pathways such as N-acetylation, which can exhibit genetically-determined variability. The objective of the present investigation was to compare the
Clinical pharmacology and therapeutics, 47(4), 470-477 (1990-04-01)
The human acetylation genotype was determined by measuring urinary caffeine metabolites by use of a modification of a previously published HPLC method. The problem of separation of 7-methylxanthine (7X) from 1-methyluric acid (IU) in urine extracts was achieved by adding
p-Phenylenediamine (PPD) has been widely distributed as hair dye ingredient and may be responsible for contact dermatitis. Since not all the subjects exposed to PPD react to the substance, we tested a possible predisposing factor of cutaneous drug metabolism. Eighty-five
Clinical pharmacology and therapeutics, 49(6), 648-657 (1991-06-01)
The use of two caffeine metabolite ratios for acetylator phenotyping was validated by demonstrating concordance with two sulfamethazine tests in 178 unrelated healthy subjects. The caffeine metabolites used for this purpose were 5-acetylamino-6-amino-3-methyluracil (AAMU), 1-methylxanthine (1X), and 1-methylurate (1U). The
Journal of pharmaceutical and biomedical analysis, 13(9), 1079-1086 (1995-08-01)
The ratio of 5-acetylamino-6-amino-3-methyluracil (AAMU) to 1-methylxanthine (1X) in urine samples after caffeine ingestion can be used to indicate human N-acetyltransferase (NAT2) phenotypes. In previous studies, this ratio has been determined by LC or capillary electrophoresis. The possibility that this
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.